Plant-Based  Proteins  with
Better Therapeutic Profiles

Protalix is dedicated to bringing to market recombinant therapeutic proteins with clinically improved profiles, produced with our ProCellEx® plant cell-based expression system

Learn more
Plant-Based  Proteins  with
Better Therapeutic Profiles Protalix is dedicated to bringing to market recombinant therapeutic proteins with clinically improved profiles, produced with our ProCellEx® plant cell-based expression system Learn more
  • Technology

    Learn more about our ProCellEx® plant cell-based protein expression system.
  • pegunigalsidase alfa

    Pegunigalsidase alfa (PRX-102) is in Phase III for the treatment of Fabry disease.
  • Alidornase alfa

    alidornase alfa (PRX-110) is being developed for inhaled indications in respiratory diseases.
  • Clinical Studies Enrollment Completed

    We have competed enrollment for all our clinical studies.

    Learn More
  • Collaborate with Protalix

    We are actively seeking collaborations for our existing pipeline or in developing new therapeutic proteins

    Contact us

 

Read the Latest Interviews with Protalix's CEO

December 2019:
PharmasAlmanac